Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Counters Accusations Involving Monsanto Weedkiller

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/06/2019 | 02:49am EDT

By Ruth Bender

BERLIN -- Monsanto Co.'s public-relations tactics in Europe didn't break the law, according to a report commissioned by Bayer AG, which continues to battle fallout from its acquisition of the U.S. agrochemical company.

The German chemicals and pharmaceuticals group said a law firm had examined allegations about Monsanto's listing of critics of the main ingredient of its Roundup weedkillers and found no wrongdoing.

Bayer has been in crisis mode since closing the Monsanto deal in 2018, with its share price falling sharply. In the past year, it has lost three jury trials alleging that Roundup causes cancer. Bayer is also facing bans in Europe on glyphosate, the weedkiller's main ingredient, due to perceived environmental risks.

A separate front opened in May after French prosecutors launched an investigation following local media reports that Monsanto and a public-relations firm had drawn up lists in 2016 of hundreds of influential French personalities, some of whom had raised concerns about possible risks posed by Monsanto's products.

While compiling so-called stakeholder lists is common practice in public relations, the media reports said they included sensitive personal information that wasn't publicly available -- the storage of which without permission can be illegal in some European Union countries. However, Bayer said Thursday that law firm Sidley Austin LLP had examined the allegations and found no evidence that the lists were illegal.

Monsanto has long been a lightning rod for environmentalists in Europe, who see it as a symbol for practices they oppose, from the genetic engineering of crops to the intensive use of pesticide in agriculture.

Bayer, which inherited that reputational baggage, has appealed the Roundup court verdicts in the U.S., insisting the product is safe when used with proper precautions. It has also criticized bans on glyphosate in Germany and Austria as unscientific.

As part of its effort to clear its name, Bayer hired Matthias Berninger, a former Green Party politician in Germany, as its head of public affairs and sustainability.

People familiar with the matter said Mr. Berninger caused consternation among former Monsanto employees in the U.S. when he publicly apologized for the company's stakeholder lists in May before it was established whether the practice was illegal.

Sidley Austin said it assessed over 2.4 million documents in relation to the lists, which included 1,500 people, mostly in the EU -- from journalists to officials working in EU institutions -- but also in the U.S.

In its 49-page report, the law firm said the lists were "detailed, methodical, and designed to strongly advocate Monsanto's positions to stakeholders and to the public." But the firm said it found no evidence of illegal surveillance of personal hobbies or leisure activities or information that went beyond what was in the public domain.

The German Council for Public Relations in July also concluded that there was no wrongdoing.

The French prosecutor's office couldn't be reached to comment on the status of its probe.

A Bayer spokesman said the French prosecutor's investigations were ongoing. The company said it hasn't been presented with formal allegations or charges from any data-protection authority or other body, either in France or elsewhere in the EU.

Write to Ruth Bender at Ruth.Bender@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
02:37aBAYER : data at ESMO 2019 highlights innovation in cancer research
PU
09/19Animal health sector aims to emulate Zoetis biotech leap
RE
09/19Biotech is going to the dogs - and big profits await
RE
09/17BAYER : Invests $20 Million in U.S.-Based Informed Data Systems
DJ
09/17BAYER : and Informed Data Systems Inc. to develop One Drop digital therapeutics ..
PU
09/11BAYER : opens application window for Grants4Traits™ and Grants4Biologicals..
PU
09/10BAYER : to reduce size of management board to five
RE
09/10BAYER : to Reduce Size of Management Board
DJ
09/10BAYER : reduces size of Board of Management from seven to five members
PU
09/10BAYER : launches latest fungicide innovation, iblon™ technology
PU
More news
Financials (EUR)
Sales 2019 46 036 M
EBIT 2019 7 933 M
Net income 2019 3 131 M
Debt 2019 37 298 M
Yield 2019 4,24%
P/E ratio 2019 21,4x
P/E ratio 2020 13,8x
EV / Sales2019 2,17x
EV / Sales2020 2,05x
Capitalization 62 695 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 78,94  €
Last Close Price 67,08  €
Spread / Highest target 83,4%
Spread / Average Target 17,7%
Spread / Lowest Target -42,2%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG9.31%68 944
JOHNSON & JOHNSON1.05%343 382
ROCHE HOLDING LTD.16.27%243 639
MERCK AND COMPANY9.89%214 995
PFIZER-16.36%201 939
NOVARTIS15.60%198 194